H.C. Wainwright initiated coverage on AngioDynamics Inc (NASDAQ:ANGO), noting that the company is debt-free and significantly undervalued compared to peers in a growing market.
AngioDynamics currently generates over 80% of its revenue from the U.S. and the rest from international markets. The analyst notes substantial room for further growth given the company’s focus on the high-growth Med Tech segment with differentiated products.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased